Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Blood (2025) 146 (Supplement 1): 7624.

https://doi.org/10.1182/blood-2025-7624

Published: 2025

Journal Articles

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Andrea Rivero, Monica Molina, Laura Julià, Víctor Navarro Garces, Juan Correa, Helena Brillembourg, Eduardo Aguilar-Meseguer, Carmen Rodríguez-Miñón, Isabel Hernández, Amanda Perez, Nuria Martinez-Cibrian, Valentin Ortiz-Maldonado, Nil Albiol, Aina Oliver-Caldes, Julio Delgado Gonzalez, Eva Gine, Pablo Mozas, Armando Lopez-Guillermo, Laura Magnano

Blood (2025) 146 (Supplement 1): 5386.

https://doi.org/10.1182/blood-2025-5386

Published: 2025

Journal Articles

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 3983.

https://doi.org/10.1182/blood-2025-3983

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Blood (2025) 146 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2025-6192

Published: 2025

Journal Articles

Patients with Chronic Lymphocytic and Non-Hematologic Autoimmune Disorders Show Distinctive Clinical and Immune Alterations in Th17 and Treg Cells

Miguel Arguello De Tomas, Elionor Lynton-Pons, Nil Albiol, Jorge Sierra, Esther Moga, Carol Moreno

Blood (2024) 144 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2024-198432

Published: 2024

Journal Articles

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Blood (2024) 144 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2024-205568

Published: 2024

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Blood (2024) 144 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2024-206082

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Patients with Chronic Lymphocytic and Non-Hematologic Autoimmune Disorders Show Distinctive Clinical and Immune Alterations in Th17 and Treg Cells

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only